# Kiora Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2021

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-K
- Filed: 2022-04-15
- Accepted by EDGAR: Apr 15, 2022, 09:06 ET
- Period: 2021-12-31
- Accession: 0001410578-22-000925
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000141057822000925/kprx-20211231x10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000141057822000925/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months, 2021-01-01 to 2021-12-31 | $5.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −$16.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2021-01-01 to 2021-12-31 | $6.9k | us-gaap:InterestExpense |
| Income tax | 12 months, 2021-01-01 to 2021-12-31 | −$304.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | −$16.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2021-01-01 to 2021-12-31 | −$1.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2021-01-01 to 2021-12-31 | −$1.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2021-01-01 to 2021-12-31 | 9,240,500 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$10.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $63.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-12-31 | $7.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $9.0m | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $18.1m | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $1.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-12-31 | $8.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-12-31 | $9.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1372514/000141057822000925/kprx-20211231x10k.htm

Filed Apr 15, 2022.
Source: SEC EDGAR, the filing index for accession 0001410578-22-000925. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
